BioMed Research International / 2016 / Article / Tab 1

Review Article

The Hedgehog Signaling Networks in Lung Cancer: The Mechanisms and Roles in Tumor Progression and Implications for Cancer Therapy

Table 1

The HH signaling pathway inhibitors.

Inhibitor NameOrganizationClinical Trial

(1) SMO inhibitors
 Cyclopamine, KAAD-cyclopamineNo
 GDC-0449 (Vismodegib/Erivedge)Roche/Genentech/CurisYes (phases 0, I, and II)
 LDE225 (Erismodegib/Sonidegib/Odomzo)NovartisYes (phases 0, I, and II)
 BMS-833923/XL139Bristol Myers Squibb/ExelixisYes (phases I and II)
 PF-04449913 (Glasdegib)PfizerYes (Phase II)
 PF-527857PfizerNo
 LY2940680 (Taladegib)IgnytaYes (phases I and II)
 IPI-926 (Sadegib)InfinityYes (phase I)
 TAK-441No
 MRT-92No
(2) GLI inhibitors
 GANT-58, GANT-61No
 Arsenic trioxide (ATO)Yes (phases I, II, III, and IV)
 HPI-1No
 Glabrescione B (GlaB)No

See [14] for description of the clinical trials of HH signaling pathway inhibitors.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.